{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:36:36Z","timestamp":1785411396667,"version":"3.56.0"},"posted":{"date-parts":[[2026,5,26]]},"group-title":"Cancer Biology","reference-count":84,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"award":["R01CA266172"],"award-info":[{"award-number":["R01CA266172"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R01CA26617S1"],"award-info":[{"award-number":["R01CA26617S1"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R01CA294651"],"award-info":[{"award-number":["R01CA294651"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R01CA206517"],"award-info":[{"award-number":["R01CA206517"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R01CA277473"],"award-info":[{"award-number":["R01CA277473"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"award":["P30CA047904"],"award-info":[{"award-number":["P30CA047904"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["R01AI171483"],"award-info":[{"award-number":["R01AI171483"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["R01AI166598"],"award-info":[{"award-number":["R01AI166598"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"award":["R35ES031638"],"award-info":[{"award-number":["R35ES031638"]}],"id":[{"id":"https:\/\/ror.org\/00j4k1h63","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003896","name":"Henry M. Jackson Foundation","doi-asserted-by":"crossref","award":["HU0001-23-2-0038"],"award-info":[{"award-number":["HU0001-23-2-0038"]}],"id":[{"id":"10.13039\/100003896","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,5,26]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>\n                  The DNA damage response kinase ATR restrains CDK1 activity during S and G2 phases of the cell cycle, confining CDK1-driven processes to mitosis. ATR kinase inhibitors were originally developed to potentiate chemotherapy-induced DNA damage at stalled replication forks and to disrupt DNA damage-induced cell cycle checkpoints. Recent evidence, however, reveals that these inhibitors also disrupt cell cycle organization in cells that have not sustained any DNA damage. We show that ATR kinase inhibitors potently trigger unscheduled mitochondrial fission, causing loss of mitochondrial mass in actively dividing CD8\n                  <jats:sup>+<\/jats:sup>\n                  T cells that persists in memory CD8\n                  <jats:sup>+<\/jats:sup>\n                  T cells. Moreover, ATR inhibition during the peak of CD8\n                  <jats:sup>+<\/jats:sup>\n                  T cell expansion in a mouse model of LCMV Armstrong infection impairs the formation of immune memory. These findings carry significant clinical implications. ATR kinase inhibitors are currently being evaluated in clinical trials in combination with chemotherapy, radiation, and immune checkpoint inhibitors in patients where anti-tumor immune responses are recognized as a determinant of durable response. Our results identify an unexpected consequence of ATR inhibition that disrupts cellular metabolism with broad implications for both preclinical research and clinical application.\n                <\/jats:p>","DOI":"10.64898\/2026.05.25.727628","type":"posted-content","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T09:40:13Z","timestamp":1779788413000},"source":"Crossref","is-referenced-by-count":0,"title":["ATR kinase inhibitors induce mitochondrial fission in CD8\n                  <sup>+<\/sup>\n                  T cells and impair immune memory\n                  <i>in vivo<\/i>"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7480-355X","authenticated-orcid":false,"given":"Frank P.","family":"Vendetti","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of Pittsburgh School of Medicine; Pittsburgh, Pennsylvania, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina R.","family":"Sclafani","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Pittsburgh School of Medicine; Pittsburgh, Pennsylvania, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqi","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Medicine, Tsinghua University; Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinakin","family":"Pandya","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Pittsburgh School of Medicine; Pittsburgh, Pennsylvania, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9839-2414","authenticated-orcid":false,"given":"Yvonne M.","family":"Mowery","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Pittsburgh School of Medicine; Pittsburgh, Pennsylvania, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Hyeong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Pittsburgh School of Medicine; Pittsburgh, Pennsylvania, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"Cumberland","sequence":"additional","affiliation":[{"name":"Department of Immunology, University of Pittsburgh School of Medicine; Pittsburgh, Pennsylvania, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satishkumar R.","family":"Ganakammal","sequence":"additional","affiliation":[{"name":"Women\u2019s Health Integrated Research Center, Women\u2019s Service Line, Inova Health System; Annandale, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4742-3281","authenticated-orcid":false,"given":"Thomas P.","family":"Conrads","sequence":"additional","affiliation":[{"name":"Women\u2019s Health Integrated Research Center, Women\u2019s Service Line, Inova Health System; Annandale, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Calderon","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, Center for Biologic Imaging, University of Pittsburgh School of Medicine; Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4092-1552","authenticated-orcid":false,"given":"Simon C.","family":"Watkins","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, Center for Biologic Imaging, University of Pittsburgh School of Medicine; Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4009-2478","authenticated-orcid":false,"given":"Bennett","family":"Van Houten","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine; Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Clump","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Pittsburgh School of Medicine; Pittsburgh, Pennsylvania, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6605-2071","authenticated-orcid":false,"given":"Robert L.","family":"Ferris","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head & Neck Surgery, University of North Carolina; Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8978-9401","authenticated-orcid":false,"given":"Jan H.","family":"Beumer","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh; Pittsburgh, PA, USA"},{"name":"Department of Oncology & Division of Clinical Pharmacology, Johns Hopkins University School of Medicine and Johns Hopkins Sidney Kimmel Cancer Center; Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2957-8135","authenticated-orcid":false,"given":"Greg M.","family":"Delgoffe","sequence":"additional","affiliation":[{"name":"Department of Immunology, University of Pittsburgh School of Medicine; Pittsburgh, Pennsylvania, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5198-516X","authenticated-orcid":false,"given":"Lawrence P.","family":"Kane","sequence":"additional","affiliation":[{"name":"Department of Immunology, University of Pittsburgh School of Medicine; Pittsburgh, Pennsylvania, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9672-0886","authenticated-orcid":false,"given":"Christopher J.","family":"Bakkenist","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Pittsburgh School of Medicine; Pittsburgh, Pennsylvania, PA, USA"},{"name":"Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine; Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026052715104156000_2026.05.25.727628v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2010.09.019"},{"key":"2026052715104156000_2026.05.25.727628v1.2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1065521"},{"key":"2026052715104156000_2026.05.25.727628v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00221-3"},{"key":"2026052715104156000_2026.05.25.727628v1.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01401-x"},{"key":"2026052715104156000_2026.05.25.727628v1.5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1903418116"},{"key":"2026052715104156000_2026.05.25.727628v1.6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aap9346"},{"issue":"12","key":"2026052715104156000_2026.05.25.727628v1.7","doi-asserted-by":"crossref","first-page":"111371","DOI":"10.1016\/j.celrep.2022.111371","article-title":"Thymidine rescues ATR kinase inhibitor-induced deoxyuridine contamination in genomic DNA, cell death, and interferon-alpha\/beta expression","volume":"40","year":"2022","journal-title":"Cell Rep"},{"key":"2026052715104156000_2026.05.25.727628v1.8","doi-asserted-by":"crossref","unstructured":"Dillon MT , Guevara J , Mohammed K , Patin EC , Smith SA , Dean E , et al. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation. J Clin Invest. 2024;134(2).","DOI":"10.1172\/JCI175369"},{"key":"2026052715104156000_2026.05.25.727628v1.9","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01187"},{"key":"2026052715104156000_2026.05.25.727628v1.10","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2158"},{"key":"2026052715104156000_2026.05.25.727628v1.11","doi-asserted-by":"crossref","unstructured":"Jo U , Arakawa Y , Zimmermann A , Taniyama D , Mizunuma M , Jenkins LM , et al. The novel ATR inhibitor M1774 induces replication protein overexpression and broad synergy with DNA-targeted anticancer drugs. Mol Cancer Ther. 2024.","DOI":"10.1158\/1535-7163.c.7311489.v1"},{"key":"2026052715104156000_2026.05.25.727628v1.12","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0019"},{"key":"2026052715104156000_2026.05.25.727628v1.13","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0239"},{"key":"2026052715104156000_2026.05.25.727628v1.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1821"},{"issue":"9","key":"2026052715104156000_2026.05.25.727628v1.15","first-page":"1424","article-title":"Bernaldo de Quiros Fernandez S, Durant ST, Cadogan EB","volume":"123","year":"2020","journal-title":"Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models. Br J Cancer"},{"key":"2026052715104156000_2026.05.25.727628v1.16","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0502"},{"key":"2026052715104156000_2026.05.25.727628v1.17","doi-asserted-by":"crossref","unstructured":"Hur J , Ghosh M , Kim TH , Park N , Pandey K , Cho YB , et al. Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer. Int J Mol Sci. 2021;22(3).","DOI":"10.3390\/ijms22031223"},{"key":"2026052715104156000_2026.05.25.727628v1.18","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0378"},{"key":"2026052715104156000_2026.05.25.727628v1.19","doi-asserted-by":"crossref","unstructured":"Suzuki T , Hirokawa T , Maeda A , Harata S , Watanabe K , Yanagita T , et al. ATR inhibitor AZD6738 increases the sensitivity of colorectal cancer cells to 5fluorouracil by inhibiting repair of DNA damage. Oncol Rep. 2022;47(4).","DOI":"10.3892\/or.2022.8289"},{"key":"2026052715104156000_2026.05.25.727628v1.20","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0010"},{"issue":"6","key":"2026052715104156000_2026.05.25.727628v1.21","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-21-2997","article-title":"ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib","volume":"82","year":"2022","journal-title":"Cancer Res"},{"key":"2026052715104156000_2026.05.25.727628v1.22","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6247"},{"key":"2026052715104156000_2026.05.25.727628v1.23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96519"},{"key":"2026052715104156000_2026.05.25.727628v1.24","doi-asserted-by":"crossref","unstructured":"Sheng H , Huang Y , Xiao Y , Zhu Z , Shen M , Zhou P , et al. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. J Immunother Cancer. 2020;8(1).","DOI":"10.1136\/jitc-2019-000340"},{"key":"2026052715104156000_2026.05.25.727628v1.25","doi-asserted-by":"crossref","unstructured":"Vendetti FP , Pandya P , Clump DA , Schamus-Haynes S , Tavakoli M , diMayorca M , et al. The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy. JCI Insight. 2023;8(4).","DOI":"10.1172\/jci.insight.165615"},{"issue":"11","key":"2026052715104156000_2026.05.25.727628v1.26","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1111\/cas.15108","article-title":"WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade","volume":"112","year":"2021","journal-title":"Cancer Sci"},{"key":"2026052715104156000_2026.05.25.727628v1.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45996-4"},{"key":"2026052715104156000_2026.05.25.727628v1.28","doi-asserted-by":"crossref","unstructured":"Patin EC , Dillon MT , Nenclares P , Grove L , Soliman H , Leslie I , et al. Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade. J Immunother Cancer. 2022;10(3).","DOI":"10.1136\/jitc-2021-004306"},{"key":"2026052715104156000_2026.05.25.727628v1.29","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado4618"},{"issue":"1","key":"2026052715104156000_2026.05.25.727628v1.30","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1186\/s12967-024-05552-6","article-title":"Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy","volume":"22","year":"2024","journal-title":"J Transl Med"},{"issue":"7","key":"2026052715104156000_2026.05.25.727628v1.31","first-page":"1307","article-title":"Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing","volume":"8","year":"2018","journal-title":"Am J Cancer Res"},{"key":"2026052715104156000_2026.05.25.727628v1.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01883-9"},{"key":"2026052715104156000_2026.05.25.727628v1.33","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019104036"},{"key":"2026052715104156000_2026.05.25.727628v1.34","doi-asserted-by":"crossref","unstructured":"Lopez JS , Harrington KJ , Im SA , Lee KW , Postel-Vinay S , Thomas JS , et al. Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC. Br J Cancer. 2026.","DOI":"10.1038\/s41416-026-03408-y"},{"key":"2026052715104156000_2026.05.25.727628v1.35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1032"},{"key":"2026052715104156000_2026.05.25.727628v1.36","doi-asserted-by":"crossref","unstructured":"Johnnidis JB , Muroyama Y , Ngiow SF , Chen Z , Manne S , Cai Z , et al. Inhibitory signaling sustains a distinct early memory CD8(+) T cell precursor that is resistant to DNA damage. Sci Immunol. 2021;6(55).","DOI":"10.1126\/sciimmunol.abe3702"},{"key":"2026052715104156000_2026.05.25.727628v1.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.08.007"},{"key":"2026052715104156000_2026.05.25.727628v1.38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1901512"},{"key":"2026052715104156000_2026.05.25.727628v1.39","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.143.2.351"},{"key":"2026052715104156000_2026.05.25.727628v1.40","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M607279200"},{"issue":"1","key":"2026052715104156000_2026.05.25.727628v1.41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00280-024-04745-6","article-title":"Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)","volume":"95","year":"2025","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026052715104156000_2026.05.25.727628v1.42","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042617-053019"},{"key":"2026052715104156000_2026.05.25.727628v1.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.06.007"},{"key":"2026052715104156000_2026.05.25.727628v1.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.05.035"},{"key":"2026052715104156000_2026.05.25.727628v1.45","doi-asserted-by":"crossref","unstructured":"Corrado M , and Pearce EL . Targeting memory T cell metabolism to improve immunity. J Clin Invest. 2022;132(1).","DOI":"10.1172\/JCI148546"},{"key":"2026052715104156000_2026.05.25.727628v1.46","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02202-x"},{"key":"2026052715104156000_2026.05.25.727628v1.47","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.8.4911-4927.2003"},{"key":"2026052715104156000_2026.05.25.727628v1.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.015"},{"issue":"96","key":"2026052715104156000_2026.05.25.727628v1.49","doi-asserted-by":"crossref","first-page":"eadj8356","DOI":"10.1126\/sciimmunol.adj8356","article-title":"Circulating KLRG1(+) long-lived effector memory T cells retain the flexibility to become tissue resident","volume":"9","year":"2024","journal-title":"Sci Immunol"},{"key":"2026052715104156000_2026.05.25.727628v1.50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1524490113"},{"key":"2026052715104156000_2026.05.25.727628v1.51","doi-asserted-by":"publisher","DOI":"10.1038\/srep12264"},{"key":"2026052715104156000_2026.05.25.727628v1.52","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20071641"},{"key":"2026052715104156000_2026.05.25.727628v1.53","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102335"},{"key":"2026052715104156000_2026.05.25.727628v1.54","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00563-6"},{"key":"2026052715104156000_2026.05.25.727628v1.55","doi-asserted-by":"crossref","first-page":"1426418","DOI":"10.3389\/fimmu.2024.1426418","article-title":"Stem-like CD8(+) T cells in cancer","volume":"15","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"2026052715104156000_2026.05.25.727628v1.56","first-page":"1","article-title":"Regulation of T cell exhaustion and stemness: molecular mechanisms and implications for cancer immunotherapy","volume":"23","year":"2026","journal-title":"Cell Mol Immunol"},{"key":"2026052715104156000_2026.05.25.727628v1.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.07.021"},{"key":"2026052715104156000_2026.05.25.727628v1.58","doi-asserted-by":"crossref","unstructured":"Wu T , Ji Y , Moseman EA , Xu HC , Manglani M , Kirby M , et al. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Sci Immunol. 2016;1(6).","DOI":"10.1126\/sciimmunol.aai8593"},{"key":"2026052715104156000_2026.05.25.727628v1.59","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-020-00707-9"},{"key":"2026052715104156000_2026.05.25.727628v1.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.05.018"},{"key":"2026052715104156000_2026.05.25.727628v1.61","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0503726102"},{"key":"2026052715104156000_2026.05.25.727628v1.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.02.010"},{"key":"2026052715104156000_2026.05.25.727628v1.63","doi-asserted-by":"crossref","unstructured":"Turner SJ , Bennett TJ , and La Gruta NL . CD8(+) T-Cell Memory: The Why, the When, and the How. Cold Spring Harb Perspect Biol. 2021;13(5).","DOI":"10.1101\/cshperspect.a038661"},{"key":"2026052715104156000_2026.05.25.727628v1.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2018.05.026"},{"key":"2026052715104156000_2026.05.25.727628v1.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.03.043"},{"key":"2026052715104156000_2026.05.25.727628v1.66","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1915108116"},{"key":"2026052715104156000_2026.05.25.727628v1.67","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2013.67"},{"key":"2026052715104156000_2026.05.25.727628v1.68","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0505-6"},{"key":"2026052715104156000_2026.05.25.727628v1.69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040690"},{"key":"2026052715104156000_2026.05.25.727628v1.70","doi-asserted-by":"crossref","unstructured":"Ho J , de Moura MB , Lin Y , Vincent G , Thorne S , Duncan LM , et al. Importance of glycolysis and oxidative phosphorylation in advanced melanoma. Mol Cancer. 2012;11:76.","DOI":"10.1186\/1476-4598-11-76"},{"key":"2026052715104156000_2026.05.25.727628v1.71","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3039"},{"key":"2026052715104156000_2026.05.25.727628v1.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.11.020"},{"key":"2026052715104156000_2026.05.25.727628v1.73","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1489"},{"key":"2026052715104156000_2026.05.25.727628v1.74","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.01.002"},{"key":"2026052715104156000_2026.05.25.727628v1.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.07.031"},{"key":"2026052715104156000_2026.05.25.727628v1.76","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.01.003"},{"key":"2026052715104156000_2026.05.25.727628v1.77","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.196"},{"key":"2026052715104156000_2026.05.25.727628v1.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2005.10.041"},{"key":"2026052715104156000_2026.05.25.727628v1.79","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1500722112"},{"key":"2026052715104156000_2026.05.25.727628v1.80","doi-asserted-by":"publisher","DOI":"10.1016\/S1534-5807(01)00055-7"},{"key":"2026052715104156000_2026.05.25.727628v1.81","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80452-3"},{"key":"2026052715104156000_2026.05.25.727628v1.82","unstructured":"Andrews S. http:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/ http:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/."},{"key":"2026052715104156000_2026.05.25.727628v1.83","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bts635"},{"key":"2026052715104156000_2026.05.25.727628v1.84","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp692"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.05.25.727628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T22:11:08Z","timestamp":1779919868000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.05.25.727628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":84,"URL":"https:\/\/doi.org\/10.64898\/2026.05.25.727628","relation":{},"subject":[],"published":{"date-parts":[[2026,5,26]]},"subtype":"preprint"}}